Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to CU20080164ApriorityCriticalpatent/CU20080164A7/en
Publication of CU20080164A7publicationCriticalpatent/CU20080164A7/en
Compuestos de dibencilamina y derivados, composiciones farmacéuticas que contienen estos compuestos y el uso de estos compuestos para elevar los niveles palsmáticos de ciertos lípidos, incluyendo el colesterol asociado a lipoproteínas de alta densidad y para reducir los niveles plasmáticos de otros lípidos, tales como el colesterol LDL y los triglicéridos y, por consiguiente, para tratar enfermedades que se exacerban por bajos niveles de colesterol-HDL y/o altos niveles de colesterol-LDL y triglicéridos, tales como aterosclerosis y enfermedades cardiovasculares en algunos mamíferos, incluyendo seres humanos.Dibenzylamine compounds and derivatives, pharmaceutical compositions containing these compounds and the use of these compounds to raise the palsmatic levels of certain lipids, including cholesterol associated with high density lipoproteins and to reduce plasma levels of other lipids, such as cholesterol LDL and triglycerides and, therefore, to treat diseases that are exacerbated by low levels of HDL-cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
CU20080164A2008-09-102008-09-10
DIBENCILAMINE COMPOUNDS AND DERIVATIVES
CU20080164A7
(en)
Pharmaceutical composition comprising a concentrated therapeutic extract, comprising phospholipids in a concentration of 60 to 99% and used to treat cardiovascular diseases, reduce triglyceride levels, reduce LDL cholesterol and increase HDL cholesterol.
COMPOUNDS DERIVED FROM 1,4-DIARILACETIDINONE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND AS A REDUCING AGENT OF CHOLESTEROL LEVELS, FOR THE TREATMENT OF LIPID METABOLISM DISORDERS, ATEROSCLEROSIS